183
Participants
Start Date
December 9, 2019
Primary Completion Date
September 1, 2022
Study Completion Date
March 10, 2023
VIB4920
Intravenous Dose 1.
Placebo
Intravenous dose matched to VIB4920.
Research Site, Lima
Research Site, Lima
Research Site, Lima
Research Site, Budapest
Research Site, Debrecen
Research Site, Gyula
Research Site, Suwon
Research site, Duncansville
Research Site, Milan
Research Site, Wheaton
Research Site, Baltimore
Research Site, Incheon
Research Site, Incheon
Research Site, Saltillo
Research Site, Brescia
Research Site, Durham
Research Site, Salisbury
Research Site, Charlotte
Research Site, Wilmington
Research Site, Lawrenceville
Research Site, Udine
Research Site, Memphis
Research Site, Taichung
Research Site, Guadalajara
Research Site, Guadalajara
Research Site, Pisa
Research Site, Kansas City
Research site, Dallas
Research Site, Houston
Research Site, Houston
Research Site, Kaohsiung City
Research site, Upland
Research Site, Fullerton
Research Site, Ahmedabad
Research Site, Pune
Research Site, Pune
Research Site, Bangalore
Research Site, Chennai
Research Site, Bhubaneswar
Research Site, Secunderabad
Research Site, Boston
Research Site, Ciudad Autonoma de Buenos Aires
Research Site, Bordeaux
Research Site, Brest
Research Site, Grenoble
Research Site, Paris
Research Site, Strasbourg
Research Site, Rome
Research Site, Perugia
Research Site, Mexico City
Research Site, Elblag
Research Site, Krakow
Research Site, Lublin
Research Site, Poznan
Research Site, Siedlce
Research Site, Szczecin
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Warsaw
Research Site, Seoul
Research Site, Newcastle upon Tyne
Research Site, Truro
Lead Sponsor
Amgen
INDUSTRY